Company intelligence / Profile preview
Ophthalmic Therapeutic Innovation
United Statesophthalmic-innovation.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
OTI is pioneering a new understanding and treatment for glaucoma by developing MMP-targeting therapeutics aimed at addressing the rate-limiting root causes of the disease. The company’s approach seeks to halt progression and improve quality of life for patients with glaucoma. No published clinical results yet.[1][4]
- Therapeutic areas
- Ophthalmology
- Modalities
- Small molecules (MMP therapeutics)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Ophthalmic Therapeutic Innovation.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ophthalmic Therapeutic Innovation.